DCP as a biomarker for TACE efficacy in hepatocellular carcinoma

DCP as a biomarker for TACE efficacy in hepatocellular carcinoma

IntroductionPrimary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.MethodsWe retrospectively analyzed 90 PHC patients treated with TACE....

Full description

Saved in:
Bibliographic Details
Main Authors: Hui Xie, Youwei Li, Jie Yang, Yuwei Tan, Jin Xu, Xiao Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Oncology
Subjects:
des-gamma-carboxyprothrombin
transarterial chemoembolization
hepatocellular carcinoma
treatment response
biomarker
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1560210/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1560210/full

Similar Items